Asia Pacific Narcolepsy Therapeutics Market Size & Outlook
The narcolepsy therapeutics market in Asia Pacific is expected to reach a projected revenue of US$ 1,488.1 million by 2030. A compound annual growth rate of 10.5% is expected of Asia Pacific narcolepsy therapeutics market from 2024 to 2030.
Asia Pacific narcolepsy therapeutics market highlights
The Asia Pacific narcolepsy therapeutics market generated a revenue of USD 743.2 million in 2023.
The market is expected to grow at a CAGR of 10.5% from 2024 to 2030.
In terms of segment, narcolepsy with cataplexy was the largest revenue generating treatment in 2023.
Narcolepsy without Cataplexy is the most lucrative treatment segment registering the fastest growth during the forecast period.
Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
Market revenue in 2023
USD 743.2 million
Market revenue in 2030
USD 1,488.1 million
Growth rate
10.5% (CAGR from 2024 to 2030)
Largest segment
Narcolepsy with cataplexy
Fastest growing segment
Narcolepsy without Cataplexy
Historical data covered
2018 - 2022
Base year for estimation
2023
Forecast period covered
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy
Key market players worldwide
Teva Pharmaceutical Industries Ltd, Jazz Pharmaceuticals PLC, Harmony Biosciences Holdings Inc Ordinary Shares, Novartis AG ADR, Janssen Pharmaceuticals, Eli Lilly and Co
Other key industry trends
In terms of revenue, Asia Pacific region accounted for 21.1% of the global narcolepsy therapeutics market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 1,488.1 million by 2030.
Asia Pacific Narcolepsy Therapeutics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Narcolepsy Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Narcolepsy With Cataplexy was the largest segment with a revenue share of 59.43% in 2023.
Horizon Databook has segmented the Asia Pacific narcolepsy therapeutics market based on narcolepsy with cataplexy, narcolepsy without cataplexy, secondary narcolepsy covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific Narcolepsy Therapeutics Market Treatment Outlook (Revenue, USD Million , 2018-2030)
Narcolepsy with Cataplexy
Narcolepsy without Cataplexy
Secondary Narcolepsy
Asia Pacific Narcolepsy Therapeutics Market Product Outlook (Revenue, USD Million , 2018-2030)
Central Nervous System stimulants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitor (SSRI)
Tricyclic antidepressants
Other Products
Reasons to subscribe to Narcolepsy Therapeutics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Narcolepsy Therapeutics Market Outlook databook
Our clientele includes a mix of Narcolepsy Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Narcolepsy Therapeutics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Narcolepsy Therapeutics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Asia Pacific Narcolepsy Therapeutics Market, 2018-2030 (US$M)